U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H17NOS
Molecular Weight 223.334
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TILETAMINE

SMILES

CCNC1(CCCCC1=O)C2=CC=CS2

InChI

InChIKey=QAXBVGVYDCAVLV-UHFFFAOYSA-N
InChI=1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3

HIDE SMILES / InChI

Molecular Formula C12H17NOS
Molecular Weight 223.334
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Tiletamine is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist chemically related to ketamine and phencyclidine. A common veterinary anesthetic drug, tiletamine is currently a Schedule III controlled substance in USA. This compound exerts sedative effects in humans and animals, also having an abuse potential, toxicity and dissociative hallucinogenic properties clinically. In combination with benzodiazepine, zolazepam it is used as veterinary drug, called as telazol. Telazol is a nonnarcotic, nonbarbiturate, injectable anesthetic agent, which is indicated in cats for restraint or for anesthesia combined with muscle relaxation and in dogs for restraint and minor procedures of short duration (30 min) requiring mild to moderate analgesia. Tiletamine exerts sedative effects in humans and animals, also having an abuse potential, toxicity and dissociative hallucinogenic properties clinically.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TELAZOL

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
30 mg 6 times / day multiple, intravenous
Abused dose
Dose: 30 mg, 6 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 6 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Disc. AE: Auditory hallucinations, Persecutory delusion...
AEs leading to
discontinuation/dose reduction:
Auditory hallucinations
Persecutory delusion
Dissociative states
Psychosis
Sources:
AEs

AEs

AESignificanceDosePopulation
Auditory hallucinations Disc. AE
30 mg 6 times / day multiple, intravenous
Abused dose
Dose: 30 mg, 6 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 6 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Dissociative states Disc. AE
30 mg 6 times / day multiple, intravenous
Abused dose
Dose: 30 mg, 6 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 6 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Persecutory delusion Disc. AE
30 mg 6 times / day multiple, intravenous
Abused dose
Dose: 30 mg, 6 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 6 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
Psychosis Disc. AE
30 mg 6 times / day multiple, intravenous
Abused dose
Dose: 30 mg, 6 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 6 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Transcriptomic analysis of the venom gland of the red-headed krait (Bungarus flaviceps) using expressed sequence tags.
2010-03-29
Dorsal arthrodesis in prepubertal New Zealand white rabbits followed to skeletal maturity: Effect on thoracic dimensions, spine growth and neural elements.
2010-01
Use of hyaluronidase to improve chemical immobilization of free-ranging polar bears (Ursus maritimus).
2010-01
Evaluation of anesthetic protocol for the collection of semen from captive collared peccaries (Tayassu tajacu) by electroejaculation.
2009-12
Effects of different general anesthetics on serum hemolysis and hepatic and muscular glycogenolysis in rats.
2009-11
The effect of amnion-derived cellular cytokine solution on the epithelialization of partial-thickness donor site wounds in normal and streptozotocin-induced diabetic swine.
2009-10-20
Movement disorder caused by abuse of veterinary anesthesia containing tiletamine.
2009-10
A serological survey of infectious disease in Yellowstone National Park's canid community.
2009-09-16
Efficacy of strain RB51 vaccine in protecting infection and vertical transmission against Brucella abortus in Sprague-Dawley rats.
2009-09
Evaluation of three immobilization combinations in the capybara (Hydrochoerus hydrochaeris).
2009-08-01
In vivo properties of the proangiogenic peptide QK.
2009-06-08
The effects of different anesthetic agents on short electroretinography protocol in dogs.
2009-06
Use of two anesthetic combinations for semen collection by electroejaculation from captive coatis (Nasua nasua).
2009-05
A pig model of acute Staphylococcus aureus induced pyemia.
2009-03-27
Comparison of azaperone-detomidine-butorphanol-ketamine and azaperone-tiletamine-zolazepam for anaesthesia in piglets.
2009-03
Biliary clearance of bromosulfophthalein in anesthetized and freely moving conscious rat.
2009-03
Urinary cortisol responses to unusual events in captive chimpanzees (Pan troglodytes).
2009-01
Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta.
2009-01
Acute effects of an alternative electronic-control-device waveform in swine.
2009
Reversible immobilization of asiatic black bear (Ursus thibetanus) with detomidine-tiletamine-zolazepam and atipamezole.
2008-12
Effects of premedication with tiletamine/zolazepam/medetomidine during general anesthesia using sevoflurane/fentanyl in swine undergoing pancreas transplantation.
2008-11
Methods of advanced wound management for care of combined traumatic and chemical warfare injuries.
2008-07-21
Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy.
2008-04-25
Biomedical evaluation of free-ranging red ruffed lemurs (Varecia rubra) within the Masoala National Park, Madagascar.
2008-03
Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis.
2008-02
Effects of acepromazine and butorphanol on tiletamine-zolazepam anesthesia in llamas.
2008-02
Effects of two different anaesthetics on serum concentrations of cortisol and luteinizing hormone in barrows and gilts.
2008-01
Changes in minimal alveolar concentration of isoflurane following treatment with medetomidine and tiletamine/zolazepam, epidural morphine or systemic buprenorphine in pigs.
2008-01
Echocardiographic reference ranges for sedated healthy cynomolgus monkeys (Macaca fascicularis).
2008-01
Antagonistic effects of yohimbine in pigs anaesthetised with tiletamine/zolazepam and xylazine.
2007-11-03
Tiletamine-zolazepam and xylazine is a potent cardiodepressive combination: a case report.
2007-11
Nitric oxide and angiotensin II receptors mediate the pressor effect of angiotensin II: a study in conscious and zoletil-anesthetized rats.
2007-11
Performance measurements in endolaparoscopic infrarenal aortic graft implantation using computer-enhanced instrumentation: a laboratory model for training.
2007-10-13
Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.
2007-06-30
Effects of tiletamine-zolazepam anaesthesia on plasma antioxidative status and some haematological parameters in sheep.
2007-06
Tiletamine-zolazepam-xylazine immobilization of fishers (Martes pennanti).
2007-04
Immobilization of Japanese black bears (Ursus thibetanus japonicus) with tiletamine hydrochloride and zolazepam hydrochloride.
2007-04
Comparison of cardiovascular effects of tiletamine-zolazepam, pentobarbital, and ketamine-xylazine in male rats.
2007-03
A comparison of anesthetic and cardiorespiratory effects of tiletamine-zolazepam-butorphanol and tiletamine-zolazepam-butorphanol- medetomidine in cats.
2007
Comparison of anesthetic and cardiorespiratory effects of tiletamine-zolazepam-butorphanol and tiletamine-zolazepam-butorphanol-medetomidine in dogs.
2007
Cardiopulmonary effects of medetomidine or midazolam in combination with ketamine or tiletamine/zolazepam for the immobilisation of captive cheetahs (Acinonyx jubatus).
2006-12
Reversible anesthesia of Southeast Asian primates with medetomidine, zolazepam, and tiletamine.
2006-12
Pharmacokinetics of tiletamine and zolazepam (Telazol) in anesthetized pigs.
2006-12
Determination of constituents of Telazol--tiletamine and zolazepam by a gas chromatography/mass spectrometry-based method.
2006-10-02
Reversible immobilization of free-ranging African lions (Panthera leo) with medetomidine-tiletamine-zolazepam and atipamezole.
2006-04
Immobilization of free-ranging maned wolf (Chrysocyon brachyurus) with tiletamine and zolazepam in central Brazil.
2006-03
Chemical immobilization of adult female Weddell seals with tiletamine and zolazepam: effects of age, condition and stage of lactation.
2006-02-09
Effects of epidural morphine and transdermal fentanyl analgesia on physiology and behaviour after abdominal surgery in pigs.
2006-01
Clinical and cardiorespiratory effects of propofol in the spotted bamboo shark (Chylloscyllium plagiosum).
2005-12
Reversible anaesthesia of free-ranging lions (Panthera leo) in Zimbabwe.
2005-12
Patents

Patents

Sample Use Guides

veterinary: Dogs: In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) TELAZOL(tiletamine HCl and zolazepam HCl) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses of TELAZOL are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg). Cats: In healthy cats, an initial TELAZOL dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovario- hysterectomy and onychectomy. When supplemental doses of TELAZOL are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg).
Route of Administration: Intramuscular
In Vitro Use Guide
Tiletamine was a potent and reversible antagonist of NMA-mediated responses without itself having major effects in low concentrations on normal membrane and synaptic pyramidal cell properties. Effects of tiletamine on synaptic transmission and on direct excitatory responses to exogenous amino acids were examined in rat hippocampal and striatal slices. In striatal slices, tiletamine inhibited the NMA-mediated, but not the spontaneous, release of [3H]acetylcholine, with an IC50 of 70 nM. In hippocampal CA1 cells, 3 microM tiletamine in the perfusate reversibly blocked the intracellularly recorded responses to ionophoretically applied NMA, but not to glutamate, quisqualate and kainate. Tiletamine, 3 to 100 microM, had no effect on the orthodromically elicited excitatory postsynaptic potential, action potential amplitude or duration, resting membrane potential, or input resistance. In Mg++-free perfusate, the excitatory postsynaptic potential was greatly augmented to give a paroxysmal depolarization shift and was reversibly blocked by 10 microM tiletamine.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:58:51 GMT 2025
Edited
by admin
on Mon Mar 31 17:58:51 GMT 2025
Record UNII
2YFC543249
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TILETAMINE [HSDB]
Preferred Name English
TILETAMINE
HSDB   INN   MI   WHO-DD  
INN  
Official Name English
2-(ETHYLAMINO)-2-(2-THIENYL)CYCLOHEXANONE
Systematic Name English
tiletamine [INN]
Common Name English
TILETAMINE [MI]
Common Name English
CYCLOHEXANONE, 2-(ETHYLAMINO)-2-(2-THIENYL)-
Systematic Name English
Tiletamine [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C245
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
Code System Code Type Description
HSDB
7638
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
FDA UNII
2YFC543249
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
MESH
D013992
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
INN
2820
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL2110703
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
WIKIPEDIA
Tiletamine
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
DRUG BANK
DB11549
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
EVMPD
SUB11050MIG
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
DAILYMED
2YFC543249
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
SMS_ID
100000082676
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
PUBCHEM
26533
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
MERCK INDEX
m10862
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY Merck Index
NCI_THESAURUS
C84211
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
RXCUI
1535217
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID5048552
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
CAS
14176-49-9
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
ECHA (EC/EINECS)
238-031-9
Created by admin on Mon Mar 31 17:58:51 GMT 2025 , Edited by admin on Mon Mar 31 17:58:51 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY